Home > Oncology > Genetic test spots high-risk invasive lobular carcinoma

Genetic test spots high-risk invasive lobular carcinoma

European Breast Cancer Conference 2020
Reuters Health - 05/10/2020 - A test that looks at the activity of 70 genes in breast tumors can help identify women with invasive lobular carcinoma (ILC) at high-risk of cancer recurrence or progression after surgery who may benefit from additional therapy, according to new research. ILC accounts for 10% of invasive breast cancers. Although most women who have surgery respond well to hormone therapy and need no further treatment, some face an increased risk of the recurrence and might benefit from chemotherapy, radiation or targeted therapies. Pinpointing this high-risk group has been "challenging," Dr. Otto Metzger of Dana-Farber Cancer Institute and Harvard Medical School in Boston, who presented the data October 2 at the virtual European Breast Cancer Conference, told Reuters Health by phone. Dr. Metzger and colleagues assessed the utility of the MammaPrint 70-gene signature test to spot high-risk women with ILC who might benefit from additional therapy. ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on